

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Manuel Rosa-Calatrava et al.)	Group Art Unit:
)	
Application No.: NEW)	Examiner:
)	
Filed: January 10, 2005)	Confirmation No.:
)	
For: MODIFIED ADENOVIRAL FIBER WITH)	
ABLATED TO CELLULAR)	
RECEPTORS)	

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date January 10, 2005

By: _____

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Substitute for form 1449A/PTO & 1449B/PTO

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number **10/520626**
 Filing Date **January 10, 2005**
 First Named Inventor **Manuel Rosa-Calatrava et al.**
 Examiner Name
 Attorney Docket Number **017753-200**

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	WO 02/096939	PCT		12-05-2002							
	WO 03/062400	PCT		07-31-2002							

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	P. LEISSNER et al., "Influence of adenoviral fiber mutations on viral encapsidation, infectivity and <i>in vivo</i> tropism," GENE THERAPY, Macmillan Press Ltd., Basingstoke, GB, Vol. 8, No. 1, 2001, pp. 49-57
	D.A. EINFELD et al., "Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions," J. VIROL., Vol. 75, No. 23, December 2001, pp. 11284-11291
	M.C. DECHECCHI et al., "Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5," J. VIROL., Vol. 75, No. 18, September 2001, pp. 8772-8780
	M.C. DECHECCHI et al., "Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions," VIROLOGY, Academic Press, Orlando, FL, Vol. 268, No. 2, 15 March 2000, pp. 382-390
	M.J. VAN RAAIJ et al., "Structure of the human adenovirus serotype 2 fiber head domain at 1.5 A resolution," VIROLOGY, Academic Press, Orlando, FL, Vol. 262, No. 2, 30 September 1999, pp. 333-343

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Attorney Docket Number

017753-200

<p>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</p>
<p>J.L. JAKUBCZAK et al., "Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells," JOURNAL OF VIROLOGY, Vol. 75, No. 6, March 2001, pp. 2972-2981</p>
<p>I. KIRBY et al., "Identification of contact residues and definition of the Car-binding site of adenovirus type 5 fiber protein...", JOURNAL OF VIROLOGY, The American Society for Microbiology, US, Vol. 74, No. 6, March 2000, pp. 2804-2813</p>
<p>I. KIRBY et al., "Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor car," JOURNAL OF VIROLOGY, The American Society for Microbiology, US, Vol. 73, No. 11, November 1999, pp. 9508-9514</p>
<p>MONIKA: "Transductional targeting with recombinant adenovirus vectors," CURRENT GENE THERAPY, Vol. 2, No. 3, September 2002, pp. 323-339</p>

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.